Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR2.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR3.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR5.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR4.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR8.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR6.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR7.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR9.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR1.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR15.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR12.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR17.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR14.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR18.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR16.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR11.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR19.htm
XML - IDEA: XBRL DOCUMENT - ESCALON MEDICAL CORPR13.htm
EX-32.2 - SECTION 906 CERTIFICATION CFO - ESCALON MEDICAL CORPd268624dex322.htm
EX-31.1 - SECTION 302 CERTIFICATION CEO - ESCALON MEDICAL CORPd268624dex311.htm
EX-32.1 - SECTION 906 CERTIFICATION CEO - ESCALON MEDICAL CORPd268624dex321.htm
EX-31.2 - SECTION 302 CERTIFICATION CFO - ESCALON MEDICAL CORPd268624dex312.htm
10-Q - FORM 10-Q - ESCALON MEDICAL CORPd268624d10q.htm
v2.4.0.6
Stock-Based Compensation
6 Months Ended
Dec. 31, 2011
Stock-Based Compensation [Abstract]  
Stock-Based Compensation
2. Stock-Based Compensation

Valuations are based upon highly subjective assumptions about the future, including stock price volatility and exercise patterns. The fair value of share-based payment awards was estimated using the Black-Scholes option pricing model. Expected volatilities are based on the historical volatility of the Company's stock. The Company uses historical data to estimate option exercise and employee terminations. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant.

 

The Company has historically granted options under the Company's option plans with an option exercise price equal to the closing market value of the stock on the date of the grant and with vesting, primarily for Company employees, either in equal annual amounts over a two- to five-year period or immediately, and, primarily for non-employee directors, immediately.

As of December 31, 2011 and 2010 total unrecognized compensation cost related to non-vested share-based compensation arrangements granted to employees under the 2004 Equity Incentive Plan was $87,726 and $234,221, respectively. The remaining cost is expected to be recognized over a weighted average period of 1.65 years. For the three-month periods ended December 31, 2011 and 2010, $16,484 and $23,898 was recorded as compensation expense, respectively. For the six-month periods ended December 31, 2011 and 2010, $40,383 and $63,257 was recorded as compensation expense, respectively.

The Company did not receive any cash from share option exercises under stock-based payment plans for the three month and six month periods ended December 31, 2011 and 2010. The Company did not realize any tax effect, which would be a reduction in its tax rate, on options due to the full valuation allowances established on its deferred tax assets.

The Company measures compensation expense for non-employee stock-based awards based on the fair value of the options issued as this is used to measure the transaction, and this is more reliable than the fair value of the services received. Fair value is measured as the value of the Company's common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty's performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. There was no non-employee compensation expense for the three-month and six-month periods ended December 31, 2011 and 2010.